小中大28 . Meyer UA: Pharmacogenetics – five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet.5,669–676 (2004). [CrossRef] [Medline]
29 . Crawford K, Alper CA: Genetics of the complement system. Rev. Immunogenet.2,323–338 (2000). [Medline]
30 . Hopken UE, Lu B, Gerard NP, Gerard C: The C5a chemoattractant receptor mediates mucosal defence to infection. Nature383,86–89 (1996). [CrossRef] [Medline]
31 . Peng Q, Li K, Patel H, Sacks SH, Zhou W: Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype. J. Immunol.176,3330–3341 (2006). [Medline]
32 . Carroll MC: The complement system in regulation of adaptive immunity. Nat. Immunol.5,981–986 (2004). [CrossRef] [Medline]
33 . Roozendaal R, Carroll MC: Complement receptors CD21 and CD35 in humoral immunity. Immunol. Rev.219,157–166 (2007). [CrossRef] [Medline]
34 . Ochs HD, Wedgwood RJ, Heller SR, Beatty PG: Complement, membrane glycoproteins, and complement receptors: their role in regulation of the immune response. Clin. Immunol Immunopathol.40,94–104 (1986). [CrossRef] [Medline]
35 . Lewis LA, Ram S, Prasad A et al.: Defining targets for complement components C4b and C3b on the pathogenic neisseriae. Infect. Immun.76,339–350 (2008). [CrossRef] [Medline]
36 . Awdeh ZL, Alper CA: Inherited polymorphism of human C4 as revealed by desialyzation. Immunobiology158,35–41 (1980). [Medline]
37 . Kopf M, Abel B, Gallimore A, Carroll M, Bachmann MF: Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat. Med.8,373–378 (2002). [CrossRef] [Medline]
38 . Beebe DP, Schreiber RD, Cooper NR: Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J. Immunol.130,1317–1322 (1983). [Medline]
39 . Niwa Y, Kanoh T: Immunological behaviour following rubella infection. Clin. Exp. Immunol.37,470–476 (1979). [Medline]
40 . Black FL, Hierholzer W, Woodall JP, Pinhiero F: Intensified reactions to measles vaccine in unexposed populations of American Indians. J. Infect. Dis.124,306–317 (1971). [Medline]
41 . Vestergaard M, Hviid A, Madsen KM et al.: MMR vaccination and febrile seizures: evaluation of susceptible subgroups and long-term prognosis. JAMA292,351–357 (2004). [CrossRef] [Medline]
42 . Kingsley JD, Varman M, Chatterjee A, Kingsley RA, Roth KS: Immunizations for patients with metabolic disorders. Pediatrics118,E460–E470 (2006). [CrossRef] [Medline]
43 . Haas RH, Parikh S, Falk MJ et al.: Mitochondrial disease: a practical approach for primary care physicians. Pediatrics120,1326–1333 (2007). [CrossRef] [Medline]
44 . Kitchener S: Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX. Vaccine22,2103–2105 (2004). [CrossRef] [Medline]
45 . Haber P, DeStefano F, Angulo FJ et al.: Guillain–Barré syndrome following influenza vaccination. JAMA292,2478–2481 (2004). [CrossRef] [Medline]
46 . Kemper AR, Davis MM, Freed GL: Expected adverse events in a mass smallpox vaccination campaign. Eff. Clin. Pract.5,84–90 (2002). [Medline]
47 . Halsell JS, Riddle JR, Atwood JE et al.: The Department of Defense Smallpox Vaccination Clinical Evaluation Team: Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA289,3283–3289 (2003). [CrossRef] [Medline]
48 . Singh R, John TJ, Cherian T, Raghupathy P: Immune response to measles, mumps & rubella vaccine at 9, 12 & 15 month